Arcellx, Inc.

News that oncologist Vinay Prasad will be the new head of the US Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) division sent biopharma shares tumbling on 6 May, as

While Gilead Sciences has seen softening of sales for its approved oncology products, the company is nevertheless showing momentum in its oncology pipeline, particularly for the CAR-T cell therapy ani

Bristol Myers Squibb is moving to take over its longtime cell therapy partner 2seventy bio and the CAR-T cell therapy they developed and commercialized together, Abecma (idecabtagene vicleucel). The b

The data that Gilead Sciences subsidiary Kite and Arcellx presented at the American Society of Hematology meeting for anitocabtagene autoleucel (anito-cel) were positive, but the question that remains